arrow
M

Mads Agerbæk

Aarhus University
H指数:35
被引数:6,356

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274

高风险肌层浸润性尿路上皮癌的辅助尼洛替尼对比安慰剂:CheckMate 274研究的5年疗效和ctDNA结果

2025-10-170
OAAI
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial

辅助性纳武利尤单抗在肌肉浸润性尿路上皮癌中的应用:随机III期CheckMate 274试验的探索性生物标志物分析

2025-08-070
PRE
Associations between patient sociodemographic characteristics and lack of treatment for locally advanced or metastatic urothelial carcinoma: results from a complete nationwide, unselected, real-world register study in Denmark

患者社会人口学特征与局部晚期或转移性尿路上皮癌缺乏治疗之间的关联:丹麦一项完整的、全国性、未筛选的真实世界登记研究的成果

2025-04-240
OA
Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma

全基因组突变分析用于尿路上皮癌患者循环肿瘤DNA的肿瘤知情检测

2024-10-012
OA
Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial

基于系列循环肿瘤DNA(ctDNA)检测,识别可能从早期根治性膀胱切除术后免疫治疗中获益的膀胱癌患者:TOMBOLA试验的初步结果

2024-09-013
PRE
[15O]H2O PET/MRI for Assessment of Complete Response to Neoadjuvant or Induction Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Pilot Study

[15O]H2O PET/MRI用于评估肌层浸润性膀胱癌患者对新辅助或诱导化疗的完全反应: 一项初步研究

2024-08-080
OAAI
Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study

临床I期睾丸非精原细胞瘤患者复发的预后因素: 一项基于人群的全国性队列研究

2024-05-013
OA
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary
2023-03-152
OA